BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 35414783)

  • 1. CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application.
    Yang YH; Liu JW; Lu C; Wei JF
    Int J Biol Sci; 2022; 18(6):2609-2626. PubMed ID: 35414783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptor-based immunotherapy in breast cancer: Recent progress in China.
    Yu T; Lu Y; Fang J; Jiang X; Lu Y; Zheng J; Shang X; Shen H; Fu P
    Cancer; 2024 Apr; 130(S8):1378-1391. PubMed ID: 37950749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
    Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook.
    Zhang H; Zhu S; Deng W; Li R; Zhou H; Xiong H
    Front Immunol; 2022; 13():887471. PubMed ID: 35935930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential of chimeric antigen receptor (CAR)-redirected immune cells in breast cancer therapies: Recent advances.
    Nikoo M; Rudiansyah M; Bokov DO; Jainakbaev NT; Suksatan W; Ansari MJ; Thangavelu L; Chupradit S; Zamani A; Adili A; Shomali N; Akbari M
    J Cell Mol Med; 2022 Aug; 26(15):4137-4156. PubMed ID: 35762299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer.
    Cao Y; Efetov SK; He M; Fu Y; Beeraka NM; Zhang J; Zhang X; Bannimath N; Chen K
    Arch Immunol Ther Exp (Warsz); 2023 Aug; 71(1):19. PubMed ID: 37566162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience.
    Sun W; Liang AB; Huang H; Huang XJ
    Haematologica; 2023 Aug; 108(8):2011-2028. PubMed ID: 36794504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer.
    He Q; Hu H; Yang F; Song D; Zhang X; Dai X
    Biomed Pharmacother; 2023 Jun; 162():114609. PubMed ID: 37001182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
    Luangwattananun P; Junking M; Sujjitjoon J; Wutti-In Y; Poungvarin N; Thuwajit C; Yenchitsomanus PT
    Breast Cancer Res Treat; 2021 Feb; 186(1):25-36. PubMed ID: 33389403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B7-H3-targeted CAR-T cell therapy for solid tumors.
    Li G; Wang H; Wu H; Chen J
    Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor T-cell therapy for breast cancer.
    Gharghani MS; Simonian M; Bakhtiari F; Ghaffari MH; Fazli G; Bayat AA; Negahdari B
    Future Oncol; 2021 Aug; 17(22):2961-2979. PubMed ID: 34156280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for lung cancer: Focusing on chimeric antigen receptor (CAR)-T cell therapy.
    Xue T; Zhao X; Zhao K; Lu Y; Yao J; Ji X
    Curr Probl Cancer; 2022 Feb; 46(1):100791. PubMed ID: 34538649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
    Qu J; Mei Q; Chen L; Zhou J
    Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
    Miao L; Zhang Z; Ren Z; Tang F; Li Y
    Front Immunol; 2021; 12():687822. PubMed ID: 34093592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
    Marofi F; Tahmasebi S; Rahman HS; Kaigorodov D; Markov A; Yumashev AV; Shomali N; Chartrand MS; Pathak Y; Mohammed RN; Jarahian M; Motavalli R; Motavalli Khiavi F
    Stem Cell Res Ther; 2021 Mar; 12(1):217. PubMed ID: 33781320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy.
    Dabas P; Danda A
    Med Oncol; 2023 Aug; 40(9):275. PubMed ID: 37608202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progression in chimeric antigen receptor T (CAR-T) cell therapy of solid tumors: A review].
    Fang Z; Han H; Liang L
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Oct; 35(10):944-948. PubMed ID: 31814572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.